BACKGROUND: We evaluated the safety and effectiveness of the hybrid thoracoscopic endocardial epicardial ablation technique for the treatment of atrial fibrillation (AF) in obese versus non-obese patients. METHODS: Between January 2010 and January 2015, a cohort of 61 patients were retrospectively identified to undergo ablation of AF as a stand-alone procedure using a thoracoscopic, hybrid epicardial-endocardial technique. All patients underwent continuous 7-day Holter monitoring at 3, 6 months, 1 year and yearly thereafter. RESULTS: A total of 40% of the obese cohort had persistent or long-standing AF, compared to 54.9% of the non-obese cohort. There were no deaths or conversion to cardiopulmonary bypass required. At 3-year follow-up, 60% of the obese group were in sinus rhythm (SR) with no episode of AF, atrial flutter or atrial tachycardia lasting 30 s off anti-arrhythmic drugs. This was compared to 70.6% in the non-obese group, with no significant difference between the groups (P=0.468). For success rates on anti-arrhythmic drugs, this was 80% in the obese group compared to 86% in the non-obese group at 3-year follow-up (P=0.637). No patient died and no thromboembolic/bleeding events or procedure-related complications occurred during the follow-up. CONCLUSIONS: In a retrospective cohort with approximately half with persistent or long-standing AF, thoracoscopic hybrid epicardial endocardial ablation proved to be equally effective and safe in obese versus non-obese patients. Current preliminary findings require further validation in multi-institutional prospective studies with larger sample sizes.
BACKGROUND: We evaluated the safety and effectiveness of the hybrid thoracoscopic endocardial epicardial ablation technique for the treatment of atrial fibrillation (AF) in obese versus non-obese patients. METHODS: Between January 2010 and January 2015, a cohort of 61 patients were retrospectively identified to undergo ablation of AF as a stand-alone procedure using a thoracoscopic, hybrid epicardial-endocardial technique. All patients underwent continuous 7-day Holter monitoring at 3, 6 months, 1 year and yearly thereafter. RESULTS: A total of 40% of the obese cohort had persistent or long-standing AF, compared to 54.9% of the non-obese cohort. There were no deaths or conversion to cardiopulmonary bypass required. At 3-year follow-up, 60% of the obese group were in sinus rhythm (SR) with no episode of AF, atrial flutter or atrial tachycardia lasting 30 s off anti-arrhythmic drugs. This was compared to 70.6% in the non-obese group, with no significant difference between the groups (P=0.468). For success rates on anti-arrhythmic drugs, this was 80% in the obese group compared to 86% in the non-obese group at 3-year follow-up (P=0.637). No patient died and no thromboembolic/bleeding events or procedure-related complications occurred during the follow-up. CONCLUSIONS: In a retrospective cohort with approximately half with persistent or long-standing AF, thoracoscopic hybrid epicardial endocardial ablation proved to be equally effective and safe in obese versus non-obese patients. Current preliminary findings require further validation in multi-institutional prospective studies with larger sample sizes.
Authors: John R Mehall; Robert M Kohut; E William Schneeberger; Tsuyoshi Taketani; Walter H Merrill; Randall K Wolf Journal: Ann Thorac Surg Date: 2007-02 Impact factor: 4.330
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: C Pappone; G Oreto; S Rosanio; G Vicedomini; M Tocchi; F Gugliotta; A Salvati; C Dicandia; M P Calabrò; P Mazzone; E Ficarra; C Di Gioia; S Gulletta; S Nardi; V Santinelli; S Benussi; O Alfieri Journal: Circulation Date: 2001-11-20 Impact factor: 29.690
Authors: Thomas J Wang; Helen Parise; Daniel Levy; Ralph B D'Agostino; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin Journal: JAMA Date: 2004-11-24 Impact factor: 56.272
Authors: Hakan Oral; Bradley P Knight; Hiroshi Tada; Mehmet Ozaydin; Aman Chugh; Sohail Hassan; Christoph Scharf; Steve W K Lai; Radmira Greenstein; Frank Pelosi; S Adam Strickberger; Fred Morady Journal: Circulation Date: 2002-03-05 Impact factor: 29.690
Authors: Nikolas Wanahita; Franz H Messerli; Sripal Bangalore; Apoor S Gami; Virend K Somers; Jonathan S Steinberg Journal: Am Heart J Date: 2007-12-19 Impact factor: 4.749
Authors: Krit Jongnarangsin; Aman Chugh; Eric Good; Siddharth Mukerji; Sujoya Dey; Thomas Crawford; Jean F Sarrazin; Michael Kuhne; Nagib Chalfoun; Darryl Wells; Warangkna Boonyapisit; Frank Pelosi; Frank Bogun; Fred Morady; Hakan Oral Journal: J Cardiovasc Electrophysiol Date: 2008-03-21
Authors: Tomasz Mazurek; LiFeng Zhang; Andrew Zalewski; John D Mannion; James T Diehl; Hwyda Arafat; Lea Sarov-Blat; Shawn O'Brien; Elizabeth A Keiper; Anthony G Johnson; Jack Martin; Barry J Goldstein; Yi Shi Journal: Circulation Date: 2003-10-27 Impact factor: 29.690
Authors: Aditya Eranki; Ashley R Wilson-Smith; Michael L Williams; Campbell D Flynn; Con Manganas Journal: J Cardiothorac Surg Date: 2022-08-13 Impact factor: 1.522